Tuberous sclerosis, also
known as tuberous sclerosis complex, is a genetic disorder characterized by the
growth of numerous noncancerous (benign) tumors in many parts of the body.
It can occur in the
brain, skin, kidneys, and other organs, in some cases leading to significant
health problems. The signs and symptoms of the disease vary from person to
person. Virtually all affected people have skin abnormalities, including
patches of unusually light-coloured skin, areas of raised and thickened skin,
and growths under the nails. It can also cause facial angiofibromas, tumors on
the face beginning in childhood.
Some affected children
have the characteristic features of autism, a developmental disorder that
affects communication and social interaction.
Get the Research Report about Tuberous Sclerosis Therapeutics At: https://www.pharmaproff.com/request-sample/1120
The drug candidates of
tuberous sclerosis disease pipeline include, but not limited to, cannabidiol,
and TAK-935. Novartis AG, GW Pharmaceuticals plc and Takeda Pharmaceutical
Company Limited are some of the major companies having drugs in the tuberous
sclerosis therapeutics pipeline.
0 Comments